Clarametyx Biosciences Email Format
Biotechnology ResearchOhio, United States11-50 Employees
Clarametyx Biosciences is a clinical-stage biotechnology company focused on developing immune-enabled biologic therapies to treat life-threatening bacterial infections. Its approach centers on a platform that targets the protective barrier around bacteria, the biofilm, with the aim of enabling the immune system to better address persistent infections. Based in Columbus, Ohio, the company operates as a small to mid-sized organization dedicated to advancing this biology into therapeutic candidates. By focusing on biofilms, Clarametyx seeks to improve outcomes for patients facing challenging bacterial infections. The company is advancing its CMTX-101 therapeutic program and a CMTX-301 vaccine program targeting DNABII proteins. In January 2025, Clarametyx appointed Douglas Thomson to its Board of Directors.